z-logo
Premium
All‐trans retinoic acid upregulates the expression of ciliary neurotrophic factor in retinal pigment epithelial cells
Author(s) -
Zhou WenDi,
Wang LuLu,
Zhou LanBo,
Bin Wei,
Bao TianPing,
Zhang Yi,
Shu Jin,
Yang WeiXia,
Hui LiangLiang,
Jin Rui,
Zhuang LiLi,
Zhou GuoPing
Publication year - 2017
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3264
Subject(s) - ciliary neurotrophic factor , retinoic acid , neurotrophic factors , retinal , retina , retinopathy of prematurity , downregulation and upregulation , biology , endocrinology , microbiology and biotechnology , medicine , cell culture , receptor , neuroscience , biochemistry , pregnancy , genetics , gestational age , gene
Retinopathy of prematurity, a leading cause of visual impairment in low birth‐weight infants, remains a crucial therapeutic challenge. Ciliary neurotrophic factor (CNTF) is a promyelinating trophic factor that promotes rod and cone photoreceptor survival and cone outer segment regeneration in the degenerating retina. Ciliary neurotrophic factor expression is regulated by many factors such as all‐trans retinoic acid (ATRA). In this study, we found that ATRA increased CNTF expression in mouse retinal pigment epithelial (RPE) cells in a dose‐ and time‐dependent manner, and PKA signaling pathway is necessary for ATRA‐induced CNTF upregulation. Furthermore, we showed that ATRA promoted CNTF expression through CREB binding to its promoter region. In addition, CNTF levels were decreased in serum of retinopathy of prematurity children and in retinal tissue of oxygen‐induced retinopathy mice. In mouse RPE cells cultured with high oxygen, CNTF expression and secretion were decreased, but could be recovered after treatment with ATRA. In conclusion, our data suggest that ATRA administration upregulates CNTF expression in RPE cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here